Valerio Therapeutics SA
SWB:C4X
Valerio Therapeutics SA
SWB:C4X
Price:
0.054
EUR
Market Cap:
€27.8m
Relative Value
The Relative Value of one
C4X
stock under the Base Case scenario is
0.027
EUR.
Compared to the current market price of 0.054 EUR,
Valerio Therapeutics SA
is
Overvalued by 49%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
C4X
Relative Value
Base Case
0.027
EUR
Overvaluation 49%
Multiples Across Competitors
C4X Competitors Multiples
Valerio Therapeutics SA Competitors
Valerio Therapeutics SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| FR |
|
Valerio Therapeutics SA
SWB:C4X
|
74.4m EUR | 40.7 | -5.7 | -28.2 | -6.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
412.3B USD | 6.7 | 98.5 | 16.1 | 22.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
207.4B USD | 5.7 | 26.9 | 15.4 | 15.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.4B USD | 6.3 | 21.9 | 13.6 | 16.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
123.9B USD | 10.4 | 31.6 | 23.9 | 24.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.1B USD | 5.8 | 18.5 | 13.9 | 15.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.9B AUD | 3.3 | 36 | 11.8 | 14.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.8B EUR | 11.3 | 36.3 | 39.6 | 40.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
